Despite the established relevance of MCL1 in neuroblastoma biology and therapy response, and 1q gain as a marker of poor prognosis [55–57] this gain was not previously linked to MCL1 activity in neuroblastoma. The gene discussed is MCL1; the disease is neuroblastoma.